evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

1,138 questions · 1,154 findings · 139 reviews · Headline outcomes only

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 184 · 15.9%GRADE not reported 183 · 15.9%Very low 273 · 23.7%Low 296 · 25.6%Moderate 171 · 14.8%High 47 · 4.1%

Brivaracetam vs placebo

Withdrawals due to adverse events · people with drug‐resistant focal epilepsy

Brivaracetam may leads to higher proportion of participants who experienced adverse events leading to… compared with placebo (low certainty).

1 finding from 1 review

Intervention not reported

Treatment withdrawal (any reason) · people with drug‐resistant focal epilepsy

The intervention showed no clear difference in treatment withdrawal (any reason) (moderate certainty).

1 finding from 1 review

Intervention not reported

Treatment withdrawal (adverse effect) · people with drug‐resistant focal epilepsy

The intervention probably leads to higher treatment withdrawal (adverse effect) (moderate certainty).

1 finding from 1 review

Ketogenic diet (KD) vs usual care

Treatment withdrawal · adults (aged 16 years and over) with drug‐resistant epilepsy

It is very uncertain whether ketogenic diet (KD) changes treatment withdrawal compared with usual care (very low certainty).

1 finding from 1 review

Vigabatrin vs placebo

50% or greater reduction in seizure frequency · people (aged 10–64 years) with drug‐resistant focal epilepsy

Vigabatrin may leads to higher ≥ 50% reduction in seizure frequency (ITT analysis) Duration of… compared with placebo (low certainty).

1 finding from 1 review

Vigabatrin vs placebo

Treatment withdrawal for any reason Duration of treatment (range): 12 (3 months) to 36 weeks · people (aged 10–64 years) with drug‐resistant focal epilepsy

It is very uncertain whether vigabatrin changes treatment withdrawal for any reason Duration of treatment (range):… compared with placebo (very low certainty).

1 finding from 1 review

Vigabatrin vs placebo

Ataxia · people (aged 10–64 years) with drug‐resistant focal epilepsy

It is very uncertain whether vigabatrin changes adverse effects: ataxia Duration of treatment (range): 7–36 weeks compared with placebo (very low certainty).

1 finding from 1 review

Vigabatrin vs placebo

Adverse effects: dizziness, lightheadedness · people (aged 10–64 years) with drug‐resistant focal epilepsy

Vigabatrin may leads to higher adverse effects: dizziness/light‐headedness Duration of treatment… compared with placebo (low certainty).

1 finding from 1 review

Vigabatrin vs placebo

Adverse effect: fatigue · people (aged 10–64 years) with drug‐resistant focal epilepsy

Vigabatrin may leads to higher adverse effects: fatigue Duration of treatment (range): 8–36 weeks compared with placebo (low certainty).

1 finding from 1 review

Vigabatrin vs placebo

Adverse effects: nystagmus Duration of treatment (range): 16–18 weeks · people (aged 10–64 years) with drug‐resistant focal epilepsy

Vigabatrin showed no clear difference in adverse effects: nystagmus Duration of treatment (range): 16–18 weeks compared with placebo (low certainty).

1 finding from 1 review

Vigabatrin vs placebo

Adverse effects: abnormal vision Duration of treatment (range): 8–36 weeks · people (aged 10–64 years) with drug‐resistant focal epilepsy

It is very uncertain whether vigabatrin changes adverse effects: abnormal vision Duration of treatment (range): 8–36… compared with placebo (very low certainty).

1 finding from 1 review